APPLICATIONS
Base Editing
Evaluate ABE and CBE strategies with early confidence
Early base editing programs are focused on achieving precise edits without introducing double-strand breaks. Multiple editors, guides and conditions are evaluated in parallel, often under pressure to move quickly.
However, assessing base editing outcomes is more complex than nuclease editing. Teams must understand where editing occurs, how efficiently it happens, and whether unintended edits or unexpected DNA damage arise in the relevant cellular context.
INDUCE-seq® is designed to support base editing programs by enabling genome-wide, cell-based assessment of editing-associated signals and unexpected DNA break events.
The workflow supports scalable, high-throughput screening approaches, allowing teams to evaluate multiple editor variants, guides and conditions in parallel while maintaining consistent, decision-ready data outputs.
Challenges with current approaches
No standard genome-wide, cell-based base editing assessment
Reliance on in silico and cell-free methods
Difficulty distinguishing true editing activity from noise
Risk of missing clinically relevant off-targets in cells
Time and cost spent validating false positives
How we can help base editing teams
Generate genome-wide, cell-based editing insight
Assess editing outcomes directly in relevant cell types
Compare editors, guides and conditions in one workflow
Reduce reliance on prediction-based methods
Enable more confident candidate selection earlier
INDUCE-seq® enables base editing teams to:
Characterize editor activity
Understand variant-specific activity patterns & timepoint-dependent changes within the same experiment, providing a mechanistic foundation for editor selection and IND-enabling characterisation.
Compare strategies in cells
Evaluate how guide choice, editor variant, dose, timepoint and delivery method influence editing outcomes, all within the same cellular context using a consistent quantitative readout.
Prioritize validation
Use a cell-based, genome-wide screen to focus validation on the most relevant off-target sites, reducing the risk of missing clinically meaningful events while avoiding pursuit of false positives that do not translate into editing activity in cells.
De-risk early
Confirm expected base editing behaviour in relevant therapeutic cell types by measuring unintended bystander editing at both on- and off-target sites.
What makes base editing different?
No intentional
¶Ù³§µþ’s
Base editors drive A→G and C→T conversions using deaminase chemistry and a nickase, without requiring donor templates or introducing DSBs.
Distinct unintended outcomes
Bystander edits, guide-dependent off-target activity and guide-independent deaminase effects create a more complex risk profile.
Multiple signals to interpret
Base editing requires capturing deamination events, associated nicking, and any unexpected DSB outcomes within the same experiment.
Cell context
matters
Editor behaviour can vary across therapeutic cell types, requiring empirical assessment in relevant human cells.
Cell-based solution purpose-built for base editing
Dedicated base editing solutions powered by INDUCE-seq®, provide end-to-end, cell-based workflows for genome-wide assessment of base editing activity.
Designed specifically for ABE and CBE programs, the platform enables simultaneous evaluation of editing-associated signals and unexpected off-target DNA break events within the same cellular context.
Built on the INDUCE-seq® platform, we have solutions providing:
End-to-end workflow from sample to actionable results
Fast turnaround to support rapid iteration
Scalability across multiple editors, guides and conditions
High sensitivity and reproducibility for genome-wide detection
Early access for base editing teams
For ABE and CBE programs, we have solutions available via early access, supporting teams looking to implement scalable, cell-based genome-wide screening for base editing programs.
